Tempus AI Completes Acquisition of Ambry Genetics

Ambry Genetics will continue operating as a wholly-owned subsidiary under its current leadership, Tempus said.

Highlights

  • Tempus AI acquired Ambry Genetics for USD 600 million in a mix of cash and stock.
  • The acquisition strengthens AI-powered genetic testing and diagnostics.
  • Financing was provided by Ares Management Credit funds.

Follow Us

Tempus AI Completes Acquisition of Ambry Genetics
Tempus AI, an artificial intelligence-driven precision medicine company, has completed its acquisition of Ambry Genetics, a genetic testing company focused on improving health by understanding the relationship between genetics and disease. The deal, valued at USD 600 million, includes USD 375 million in cash and USD 225 million in shares, with USD 100 million subject to a one-year lock-up. Financing was provided by Ares Management Credit Funds.

Also Read: Corti Launches Specialised AI Models for Healthcare




Tempus AI Acquires Ambry Genetics

The acquisition strengthens Tempus' ability to integrate AI-powered analytics with genetic testing, enhancing diagnostics and patient care. Ambry Genetics will continue operating as a wholly-owned subsidiary under its current leadership, Tempus announced on Monday.

"This acquisition complements our strategy of leveraging diagnostics and data to drive innovation, further strengthening our ability to deliver cutting-edge solutions to clinicians, patients, and life sciences companies," said Eric Lefkofsky, Founder and CEO of Tempus.

Also Read: Meta Says Open-Source AI Is Transforming Healthcare Outcomes

Tempus AI Abilities

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of multimodal data and an operating system to make that data accessible and useful, Tempus says it provides AI-enabled precision medicine solutions to physicians to deliver personalised patient care while facilitating the discovery, development and delivery of optimal therapeutics.

Reported By

Kirpa B is passionate about the latest advancements in Artificial Intelligence technologies and has a keen interest in telecom. In her free time, she enjoys gardening or diving into insightful articles on AI.

Recent Comments

Manan Ganatra :

From which date it will be implemented

Vodafone Idea Voice-Centric Plans in January 2025 Detailed

Faraz :

Yup .. Earlier Jio didn't talk about ARPU.. Vi was more concerned about saving business and generating revenue over ARPU.…

Airtel Prepaid Plans with 84 Days Validity: February 2025 Edition

Faraz :

BSNL customer loss in December & January will be devastating.

BSNL Provides Free SIM Cards to Pilgrims, Strengthens Infrastructure at…

Sujata :

BSNL will kepp on loosing and gaining, all thanks to make in india 4g

BSNL Provides Free SIM Cards to Pilgrims, Strengthens Infrastructure at…

Load More
Subscribe
Notify of
guest

0 Comments
Inline Feedbacks
View all comments